Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Early Phase 1
2(28.6%)
7Total
Phase 1(5)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06134960Phase 1Not Yet Recruiting

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

Role: collaborator

NCT05583201Early Phase 1Recruiting

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Role: collaborator

NCT05382377Early Phase 1Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Role: collaborator

NCT05131763Phase 1Unknown

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Role: collaborator

NCT04270461Phase 1Withdrawn

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Role: collaborator

NCT04550663Phase 1Unknown

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Role: collaborator

NCT03854994Phase 1Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Role: collaborator

All 7 trials loaded